When does patent for saxenda expire?

When is Saxenda’s main patent set to expire?
The U.S. patent that protects Saxenda (liraglutide for obesity) is slated to expire in 2027. This is the date most frequently cited in recent patent‑watch listings.

What patents keep Saxenda exclusive?
Novo Nordisk holds several patents that cover the drug’s formulation, dosing, and use for weight management. The most prominent is a combination product patent that extends protection beyond the original liraglutide patents for diabetes. These patents are the ones that prevent other manufacturers from producing a generic Saxenda until the 2027 expiry.

Will biosimilars enter the market next year?
Biosimilars can only be approved once the relevant patents expire. With the primary patent expiring in 2027, the first biosimilar Saxenda is likely to seek approval a year or two later, assuming all regulatory and commercial hurdles are met.

Does the expiration vary by country?
Yes. Patent term extensions and regulatory approval timelines differ internationally. In the European Union, for instance, the Saxenda patents are expected to last a few months longer, potentially pushing the first generic entry to 2028 or 2029.

What happens after the patent expires?
Once the patents lapse, other manufacturers can file for generic approval, potentially lowering treatment costs. Novo Nordisk may also launch lower‑price versions or new indications to extend market share, but the main barrier—patent exclusivity—will be gone.

Source: DrugPatentWatch.com